Cantor Fitzgerald Estimates Biohaven FY2026 Earnings

Biohaven Ltd. (NYSE:BHVN - Free Report) - Investment analysts at Cantor Fitzgerald issued their FY2026 earnings estimates for shares of Biohaven in a research report issued on Monday, June 9th. Cantor Fitzgerald analyst P. Stavropoulos forecasts that the company will post earnings per share of ($6.65) for the year. Cantor Fitzgerald has a "Strong-Buy" rating on the stock. The consensus estimate for Biohaven's current full-year earnings is ($8.90) per share.

Several other brokerages also recently issued reports on BHVN. Morgan Stanley lowered their price objective on shares of Biohaven from $69.00 to $63.00 and set an "overweight" rating on the stock in a research note on Friday, March 7th. Robert W. Baird reduced their price target on shares of Biohaven from $60.00 to $57.00 and set an "outperform" rating for the company in a report on Monday, April 28th. JPMorgan Chase & Co. dropped their price objective on shares of Biohaven from $72.00 to $68.00 and set an "overweight" rating on the stock in a report on Wednesday, March 5th. Deutsche Bank Aktiengesellschaft set a $60.00 target price on shares of Biohaven and gave the company a "buy" rating in a research note on Thursday, March 20th. Finally, HC Wainwright restated a "buy" rating and set a $54.00 price target on shares of Biohaven in a research note on Tuesday, March 4th. One analyst has rated the stock with a hold rating, twelve have issued a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat, Biohaven has a consensus rating of "Buy" and a consensus target price of $59.46.

Biohaven Trading Down 1.7%

BHVN traded down $0.29 during midday trading on Tuesday, reaching $16.78. The company's stock had a trading volume of 1,604,606 shares, compared to its average volume of 1,245,970. The company has a fifty day simple moving average of $18.41 and a 200 day simple moving average of $30.35. The stock has a market cap of $1.71 billion, a P/E ratio of -1.79 and a beta of 0.95. Biohaven has a twelve month low of $14.33 and a twelve month high of $55.70.

Biohaven (NYSE:BHVN - Get Free Report) last posted its quarterly earnings data on Monday, May 12th. The company reported ($2.17) EPS for the quarter, missing analysts' consensus estimates of ($1.67) by ($0.50).

Institutional Trading of Biohaven

Several institutional investors have recently bought and sold shares of BHVN. JPMorgan Chase & Co. lifted its holdings in shares of Biohaven by 144.5% during the fourth quarter. JPMorgan Chase & Co. now owns 1,979,169 shares of the company's stock valued at $73,922,000 after acquiring an additional 1,169,721 shares during the period. Norges Bank acquired a new stake in shares of Biohaven during the 4th quarter worth about $33,711,000. Millennium Management LLC lifted its holdings in Biohaven by 1,172.9% during the 1st quarter. Millennium Management LLC now owns 901,258 shares of the company's stock valued at $21,666,000 after purchasing an additional 830,457 shares during the last quarter. Farallon Capital Management LLC boosted its position in Biohaven by 21.6% in the fourth quarter. Farallon Capital Management LLC now owns 4,428,167 shares of the company's stock valued at $165,392,000 after buying an additional 785,578 shares in the last quarter. Finally, Janus Henderson Group PLC boosted its position in Biohaven by 12.1% in the fourth quarter. Janus Henderson Group PLC now owns 6,982,425 shares of the company's stock valued at $260,735,000 after buying an additional 756,032 shares in the last quarter. Institutional investors and hedge funds own 88.78% of the company's stock.

Biohaven Company Profile

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.